Publications by authors named "M Y van der Klift"
With the increasing prevalence of comorbidity in an ageing population, it is crucial to better understand the impact of comorbidity on health-related quality of life (HRQoL) after lymphoma or multiple myeloma (MM) diagnosis. We included 261 newly diagnosed patients (67% response rate) diagnosed with lymphoma or MM between October 2020 and March 2023 in a longitudinal survey. The European Organisation for Research and Treatment of Cancer (EORTC) questionnaires were used to measure generic and disease-specific HRQoL.
View Article and Find Full Text PDFChronic lymphocytic leukemia (CLL)-related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to geriatric characteristics and aim for an improvement in health-related quality of life (HRQoL) as a primary treatment goal. In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67).
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of venetoclax combined with anti-CD20 antibodies in fit patients with advanced chronic lymphocytic leukemia (CLL), compared to traditional chemoimmunotherapy.
- In a phase 3 trial with 926 participants, various treatment regimens were compared, emphasizing the primary goals of achieving undetectable minimal residual disease and prolonging progression-free survival.
- Results showed that venetoclax combinations significantly outperformed chemoimmunotherapy in terms of undetectable minimal residual disease rates and 3-year progression-free survival, especially in the venetoclax-obinutuzumab-ibrutinib group.